Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort: Liver International

A. Soria; M. Fava; D.P. Bernasconi; G. Lapadula; E. Colella; M.G. Valsecchi; G.M. Migliorino; R. D'Ambrosio; S. Landonio; M. Schiavini; A. Spinetti; C. Carriero; E. Degasperi; G. Cologni; F. Gatti; P. Viganò; H. Hasson; C. Uberti-Foppa; L. Pasulo; C. Baiguera; R. Rossotti; M. Vinci; M. Puoti; A. Giorgini; B. Menzaghi; A. Lombardi; A. Pan; A. Aghemo; P.A. Grossi; R. Boldizzoni; S. Colombo; M. Viganò; M.G. Rumi; P. Del Poggio; L. Valenti; O. Giglio; A. De Bona; A. d'Arminio Monforte; A. Colombo; O. Spinelli; M.G. Pigozzi; C. Molteni; P. Bonfanti; N. Terreni; P. Perini; A. Capretti; D. Bella; C. Liani; S. Polo; G. Aimo; L. Pagnucco; S. Bhoori; R. Centenaro; M. Graffeo; A. Ciaccio; E. Dionigi; S. Lazzaroni; I. Carderi; M. Di Marco; G. Rizzardini; F. Noventa; P. Lampertico; S. Fagiuoli

doi:10.1111/liv.14386

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort: Liver International

A. Soria, M. Fava, D.P. Bernasconi, G. Lapadula, E. Colella, M.G. Valsecchi, G.M. Migliorino, R. D'Ambrosio, S. Landonio, M. Schiavini, A. Spinetti, C. Carriero, E. Degasperi, G. Cologni, F. Gatti, P. Viganò, H. Hasson, C. Uberti-Foppa, L. Pasulo, C. BaigueraR. Rossotti, M. Vinci, M. Puoti, A. Giorgini, B. Menzaghi, A. Lombardi, A. Pan, A. Aghemo, P.A. Grossi, R. Boldizzoni, S. Colombo, M. Viganò, M.G. Rumi, P. Del Poggio, L. Valenti, O. Giglio, A. De Bona, A. d'Arminio Monforte, A. Colombo, O. Spinelli, M.G. Pigozzi, C. Molteni, P. Bonfanti, N. Terreni, P. Perini, A. Capretti, D. Bella, C. Liani, S. Polo, G. Aimo, L. Pagnucco, S. Bhoori, R. Centenaro, M. Graffeo, A. Ciaccio, E. Dionigi, S. Lazzaroni, I. Carderi, M. Di Marco, G. Rizzardini, F. Noventa, P. Lampertico, S. Fagiuoli

Research output: Contribution to journal › Article › peer-review

Abstract

Background & Aims: In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap. Methods: Sustained virological response 12 weeks after treatment completion (SVR12) was assessed for all HCV-GT3 patients consecutively treated within the Lombardia web-based Navigatore HCV-Network; differences in SVR12 across regimens were evaluated by logistic regression. Results: Of the 2082 subjects with HCV-GT3, 1544 were evaluable for comparisons between regimens: SOF + DAC (1023, 66.2%), SOF/VEL (369, 23.9%), GLE/PIB (152, 9.8%). Patients treated with former regimens were more frequently male, cirrhotic, HIV-positive, pretreated, used ribavirin in their regimen, and had lower baseline HCV-RNA. SVR12 was similar across groups: 94.8% in SOF + DAC, 97.6% in SOF/VEL, 96.7% in GLE/PIB (P =.065). At univariate analysis, SVR12 was associated with female gender (97.9% vs 94.8%, P =.007) and lower median pretreatment Log10HCV-RNA (5.87 vs 6.20, P =.001). At multivariate logistic regression analysis, treatment with SOF/VEL was associated with a higher likelihood of SVR12 than SOF + DAC, but only in the absence of ribavirin (98% vs 90.3%). Female gender and lower pretreatment HCV-RNA were independently associated with SVR12. Conclusions: In a large real-life setting of HCV-GT3-infected patients with a high proportion of cirrhosis, the success rate was remarkable. The slight advantage of SOF/VEL on SOF + DAC was significant only without ribavirin. The current prescription shift towards novel regimens (ie SOF/VEL and GLE/PIB) in easier-to-treat patients allows ribavirin-free and shorter schedules without mining SVR12 in this <<difficult-to-treat>> genotype. © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Original language	English
Pages (from-to)	769-777
Number of pages	9
Journal	Liver Int.
Volume	40
Issue number	4
DOIs	https://doi.org/10.1111/liv.14386
Publication status	Published - 2020

Keywords

daclatasvir
genotype 3
glecaprevir
Hepatitis C
pibrentasvir
ribavirin
sofosbuvir
sustained virological response
velpatasvir
daclatasvir plus sofosbuvir
glecaprevir plus pibrentasvir
sofosbuvir plus velpatasvir
unclassified drug
virus RNA
adult
antiviral therapy
Article
cohort analysis
comparative effectiveness
female
hepatitis C
Hepatitis C virus genotype 3
human
Human immunodeficiency virus infected patient
liver cirrhosis
longitudinal study
major clinical study
male
multicenter study
sex difference
sustained virologic response
treatment duration
treatment response

Access to Document

10.1111/liv.14386

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078844599&doi=10.1111%2fliv.14386&partnerID=40&md5=c4a4fd2b83e7b348aaf0f9d0b3311381

Cite this

Soria, A., Fava, M., Bernasconi, D. P., Lapadula, G., Colella, E., Valsecchi, M. G., Migliorino, G. M., D'Ambrosio, R., Landonio, S., Schiavini, M., Spinetti, A., Carriero, C., Degasperi, E., Cologni, G., Gatti, F., Viganò, P., Hasson, H., Uberti-Foppa, C., Pasulo, L., ... Fagiuoli, S. (2020). Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort: Liver International. Liver Int., 40(4), 769-777. https://doi.org/10.1111/liv.14386

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort : Liver International. / Soria, A.; Fava, M.; Bernasconi, D.P.; Lapadula, G.; Colella, E.; Valsecchi, M.G.; Migliorino, G.M.; D'Ambrosio, R.; Landonio, S.; Schiavini, M.; Spinetti, A.; Carriero, C.; Degasperi, E.; Cologni, G.; Gatti, F.; Viganò, P.; Hasson, H.; Uberti-Foppa, C.; Pasulo, L.; Baiguera, C.; Rossotti, R.; Vinci, M.; Puoti, M.; Giorgini, A.; Menzaghi, B.; Lombardi, A.; Pan, A.; Aghemo, A.; Grossi, P.A.; Boldizzoni, R.; Colombo, S.; Viganò, M.; Rumi, M.G.; Del Poggio, P.; Valenti, L.; Giglio, O.; De Bona, A.; d'Arminio Monforte, A.; Colombo, A.; Spinelli, O.; Pigozzi, M.G.; Molteni, C.; Bonfanti, P.; Terreni, N.; Perini, P.; Capretti, A.; Bella, D.; Liani, C.; Polo, S.; Aimo, G.; Pagnucco, L.; Bhoori, S.; Centenaro, R.; Graffeo, M.; Ciaccio, A.; Dionigi, E.; Lazzaroni, S.; Carderi, I.; Di Marco, M.; Rizzardini, G.; Noventa, F.; Lampertico, P.; Fagiuoli, S.

In: Liver Int., Vol. 40, No. 4, 2020, p. 769-777.

Research output: Contribution to journal › Article › peer-review

Soria, A, Fava, M, Bernasconi, DP, Lapadula, G, Colella, E, Valsecchi, MG, Migliorino, GM, D'Ambrosio, R, Landonio, S, Schiavini, M, Spinetti, A, Carriero, C, Degasperi, E, Cologni, G, Gatti, F, Viganò, P, Hasson, H , Uberti-Foppa, C, Pasulo, L, Baiguera, C, Rossotti, R, Vinci, M, Puoti, M, Giorgini, A, Menzaghi, B, Lombardi, A, Pan, A, Aghemo, A, Grossi, PA, Boldizzoni, R, Colombo, S, Viganò, M, Rumi, MG, Del Poggio, P, Valenti, L, Giglio, O, De Bona, A, d'Arminio Monforte, A, Colombo, A, Spinelli, O, Pigozzi, MG, Molteni, C, Bonfanti, P, Terreni, N, Perini, P, Capretti, A, Bella, D, Liani, C, Polo, S, Aimo, G, Pagnucco, L , Bhoori, S, Centenaro, R, Graffeo, M, Ciaccio, A, Dionigi, E, Lazzaroni, S, Carderi, I, Di Marco, M, Rizzardini, G, Noventa, F, Lampertico, P & Fagiuoli, S 2020, 'Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort: Liver International', Liver Int., vol. 40, no. 4, pp. 769-777. https://doi.org/10.1111/liv.14386

Soria, A. ; Fava, M. ; Bernasconi, D.P. ; Lapadula, G. ; Colella, E. ; Valsecchi, M.G. ; Migliorino, G.M. ; D'Ambrosio, R. ; Landonio, S. ; Schiavini, M. ; Spinetti, A. ; Carriero, C. ; Degasperi, E. ; Cologni, G. ; Gatti, F. ; Viganò, P. ; Hasson, H. ; Uberti-Foppa, C. ; Pasulo, L. ; Baiguera, C. ; Rossotti, R. ; Vinci, M. ; Puoti, M. ; Giorgini, A. ; Menzaghi, B. ; Lombardi, A. ; Pan, A. ; Aghemo, A. ; Grossi, P.A. ; Boldizzoni, R. ; Colombo, S. ; Viganò, M. ; Rumi, M.G. ; Del Poggio, P. ; Valenti, L. ; Giglio, O. ; De Bona, A. ; d'Arminio Monforte, A. ; Colombo, A. ; Spinelli, O. ; Pigozzi, M.G. ; Molteni, C. ; Bonfanti, P. ; Terreni, N. ; Perini, P. ; Capretti, A. ; Bella, D. ; Liani, C. ; Polo, S. ; Aimo, G. ; Pagnucco, L. ; Bhoori, S. ; Centenaro, R. ; Graffeo, M. ; Ciaccio, A. ; Dionigi, E. ; Lazzaroni, S. ; Carderi, I. ; Di Marco, M. ; Rizzardini, G. ; Noventa, F. ; Lampertico, P. ; Fagiuoli, S. / Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort : Liver International. In: Liver Int. 2020 ; Vol. 40, No. 4. pp. 769-777.

@article{56fa08b163bd4f2698e59fcc2bd3cf6d,

title = "Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort: Liver International",

abstract = "Background & Aims: In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap. Methods: Sustained virological response 12 weeks after treatment completion (SVR12) was assessed for all HCV-GT3 patients consecutively treated within the Lombardia web-based Navigatore HCV-Network; differences in SVR12 across regimens were evaluated by logistic regression. Results: Of the 2082 subjects with HCV-GT3, 1544 were evaluable for comparisons between regimens: SOF + DAC (1023, 66.2%), SOF/VEL (369, 23.9%), GLE/PIB (152, 9.8%). Patients treated with former regimens were more frequently male, cirrhotic, HIV-positive, pretreated, used ribavirin in their regimen, and had lower baseline HCV-RNA. SVR12 was similar across groups: 94.8% in SOF + DAC, 97.6% in SOF/VEL, 96.7% in GLE/PIB (P =.065). At univariate analysis, SVR12 was associated with female gender (97.9% vs 94.8%, P =.007) and lower median pretreatment Log10HCV-RNA (5.87 vs 6.20, P =.001). At multivariate logistic regression analysis, treatment with SOF/VEL was associated with a higher likelihood of SVR12 than SOF + DAC, but only in the absence of ribavirin (98% vs 90.3%). Female gender and lower pretreatment HCV-RNA were independently associated with SVR12. Conclusions: In a large real-life setting of HCV-GT3-infected patients with a high proportion of cirrhosis, the success rate was remarkable. The slight advantage of SOF/VEL on SOF + DAC was significant only without ribavirin. The current prescription shift towards novel regimens (ie SOF/VEL and GLE/PIB) in easier-to-treat patients allows ribavirin-free and shorter schedules without mining SVR12 in this <> genotype. {\textcopyright} 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

keywords = "daclatasvir, genotype 3, glecaprevir, Hepatitis C, pibrentasvir, ribavirin, sofosbuvir, sustained virological response, velpatasvir, daclatasvir plus sofosbuvir, glecaprevir plus pibrentasvir, sofosbuvir plus velpatasvir, unclassified drug, virus RNA, adult, antiviral therapy, Article, cohort analysis, comparative effectiveness, female, hepatitis C, Hepatitis C virus genotype 3, human, Human immunodeficiency virus infected patient, liver cirrhosis, longitudinal study, major clinical study, male, multicenter study, sex difference, sustained virologic response, treatment duration, treatment response",

author = "A. Soria and M. Fava and D.P. Bernasconi and G. Lapadula and E. Colella and M.G. Valsecchi and G.M. Migliorino and R. D'Ambrosio and S. Landonio and M. Schiavini and A. Spinetti and C. Carriero and E. Degasperi and G. Cologni and F. Gatti and P. Vigan{\`o} and H. Hasson and C. Uberti-Foppa and L. Pasulo and C. Baiguera and R. Rossotti and M. Vinci and M. Puoti and A. Giorgini and B. Menzaghi and A. Lombardi and A. Pan and A. Aghemo and P.A. Grossi and R. Boldizzoni and S. Colombo and M. Vigan{\`o} and M.G. Rumi and {Del Poggio}, P. and L. Valenti and O. Giglio and {De Bona}, A. and {d'Arminio Monforte}, A. and A. Colombo and O. Spinelli and M.G. Pigozzi and C. Molteni and P. Bonfanti and N. Terreni and P. Perini and A. Capretti and D. Bella and C. Liani and S. Polo and G. Aimo and L. Pagnucco and S. Bhoori and R. Centenaro and M. Graffeo and A. Ciaccio and E. Dionigi and S. Lazzaroni and I. Carderi and {Di Marco}, M. and G. Rizzardini and F. Noventa and P. Lampertico and S. Fagiuoli",

note = "Cited By :4 Export Date: 11 March 2021 CODEN: LIINC Correspondence Address: Soria, A.; Division of Infectious Diseases, Italy; email: a.soria@asst-monza.it Chemicals/CAS: daclatasvir, 1009119-64-5, 1009119-65-6; ribavirin, 36791-04-5; sofosbuvir, 1190307-88-0 Funding details: Bayer Funding details: GlaxoSmithKline, GSK Funding details: Novartis Funding details: Gilead Sciences Funding details: AbbVie Funding details: Meso Scale Diagnostics, MSD Funding text 1: Alessandro Soria: Advisory Board: AbbVie; Speaker: MSD, AbbVie; Travel Support: Gilead, MSD, Abbvie; Elisabetta Degasperi: Speaker: AbbVie, Gilead, MSD; Research Grants: Gilead; Travel Support: AbbVie; Luisa Pasulo: Advisory Board: AbbVie; Maria Vinci: Advisory Board: AbbVie; Grant: AbbVie; Massimo Puoti: Speaker's bureau and Advisory: AbbVie, BMS, Boehringer Ingelheim, Janssen, Gilead, MSD, Roche; Research Grant: Gilead, MSD; Alessia Giorgini: Speaker: AbbVie, MSD, Gilead; Advisory Board: AbbVie; Alessio Aghemo: Speaker's bureau and Advisory: AbbVie, Gilead, Intercept, Alfasigma, MSD; Paolo Bonfanti: Speaker: MSD, Gilead; Advisory Board MSD, Gilead; Pietro Lampertico: Speaker's bureau and Advisory: AbbVie, BMS, Gilead, GSK, Janssen, MSD, Roche; Stefano Fagiuoli: Speaker's bureau and Advisory: Gilead, AbbVie, MSD, Bayer, Novartis, Kedrion, Intercept, Astellas. All the other authors have nothing to disclose.",

year = "2020",

doi = "10.1111/liv.14386",

language = "English",

volume = "40",

pages = "769--777",

journal = "Liver Int.",

issn = "1478-3223",

publisher = "Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

T2 - Liver International

AU - Soria, A.

AU - Fava, M.

AU - Bernasconi, D.P.

AU - Lapadula, G.

AU - Colella, E.

AU - Valsecchi, M.G.

AU - Migliorino, G.M.

AU - D'Ambrosio, R.

AU - Landonio, S.

AU - Schiavini, M.

AU - Spinetti, A.

AU - Carriero, C.

AU - Degasperi, E.

AU - Cologni, G.

AU - Gatti, F.

AU - Viganò, P.

AU - Hasson, H.

AU - Uberti-Foppa, C.

AU - Pasulo, L.

AU - Baiguera, C.

AU - Rossotti, R.

AU - Vinci, M.

AU - Puoti, M.

AU - Giorgini, A.

AU - Menzaghi, B.

AU - Lombardi, A.

AU - Pan, A.

AU - Aghemo, A.

AU - Grossi, P.A.

AU - Boldizzoni, R.

AU - Colombo, S.

AU - Viganò, M.

AU - Rumi, M.G.

AU - Del Poggio, P.

AU - Valenti, L.

AU - Giglio, O.

AU - De Bona, A.

AU - d'Arminio Monforte, A.

AU - Colombo, A.

AU - Spinelli, O.

AU - Pigozzi, M.G.

AU - Molteni, C.

AU - Bonfanti, P.

AU - Terreni, N.

AU - Perini, P.

AU - Capretti, A.

AU - Bella, D.

AU - Liani, C.

AU - Polo, S.

AU - Aimo, G.

AU - Pagnucco, L.

AU - Bhoori, S.

AU - Centenaro, R.

AU - Graffeo, M.

AU - Ciaccio, A.

AU - Dionigi, E.

AU - Lazzaroni, S.

AU - Carderi, I.

AU - Di Marco, M.

AU - Rizzardini, G.

AU - Noventa, F.

AU - Lampertico, P.

AU - Fagiuoli, S.

N1 - Cited By :4 Export Date: 11 March 2021 CODEN: LIINC Correspondence Address: Soria, A.; Division of Infectious Diseases, Italy; email: a.soria@asst-monza.it Chemicals/CAS: daclatasvir, 1009119-64-5, 1009119-65-6; ribavirin, 36791-04-5; sofosbuvir, 1190307-88-0 Funding details: Bayer Funding details: GlaxoSmithKline, GSK Funding details: Novartis Funding details: Gilead Sciences Funding details: AbbVie Funding details: Meso Scale Diagnostics, MSD Funding text 1: Alessandro Soria: Advisory Board: AbbVie; Speaker: MSD, AbbVie; Travel Support: Gilead, MSD, Abbvie; Elisabetta Degasperi: Speaker: AbbVie, Gilead, MSD; Research Grants: Gilead; Travel Support: AbbVie; Luisa Pasulo: Advisory Board: AbbVie; Maria Vinci: Advisory Board: AbbVie; Grant: AbbVie; Massimo Puoti: Speaker's bureau and Advisory: AbbVie, BMS, Boehringer Ingelheim, Janssen, Gilead, MSD, Roche; Research Grant: Gilead, MSD; Alessia Giorgini: Speaker: AbbVie, MSD, Gilead; Advisory Board: AbbVie; Alessio Aghemo: Speaker's bureau and Advisory: AbbVie, Gilead, Intercept, Alfasigma, MSD; Paolo Bonfanti: Speaker: MSD, Gilead; Advisory Board MSD, Gilead; Pietro Lampertico: Speaker's bureau and Advisory: AbbVie, BMS, Gilead, GSK, Janssen, MSD, Roche; Stefano Fagiuoli: Speaker's bureau and Advisory: Gilead, AbbVie, MSD, Bayer, Novartis, Kedrion, Intercept, Astellas. All the other authors have nothing to disclose.

PY - 2020

Y1 - 2020

N2 - Background & Aims: In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap. Methods: Sustained virological response 12 weeks after treatment completion (SVR12) was assessed for all HCV-GT3 patients consecutively treated within the Lombardia web-based Navigatore HCV-Network; differences in SVR12 across regimens were evaluated by logistic regression. Results: Of the 2082 subjects with HCV-GT3, 1544 were evaluable for comparisons between regimens: SOF + DAC (1023, 66.2%), SOF/VEL (369, 23.9%), GLE/PIB (152, 9.8%). Patients treated with former regimens were more frequently male, cirrhotic, HIV-positive, pretreated, used ribavirin in their regimen, and had lower baseline HCV-RNA. SVR12 was similar across groups: 94.8% in SOF + DAC, 97.6% in SOF/VEL, 96.7% in GLE/PIB (P =.065). At univariate analysis, SVR12 was associated with female gender (97.9% vs 94.8%, P =.007) and lower median pretreatment Log10HCV-RNA (5.87 vs 6.20, P =.001). At multivariate logistic regression analysis, treatment with SOF/VEL was associated with a higher likelihood of SVR12 than SOF + DAC, but only in the absence of ribavirin (98% vs 90.3%). Female gender and lower pretreatment HCV-RNA were independently associated with SVR12. Conclusions: In a large real-life setting of HCV-GT3-infected patients with a high proportion of cirrhosis, the success rate was remarkable. The slight advantage of SOF/VEL on SOF + DAC was significant only without ribavirin. The current prescription shift towards novel regimens (ie SOF/VEL and GLE/PIB) in easier-to-treat patients allows ribavirin-free and shorter schedules without mining SVR12 in this <> genotype. © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

AB - Background & Aims: In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap. Methods: Sustained virological response 12 weeks after treatment completion (SVR12) was assessed for all HCV-GT3 patients consecutively treated within the Lombardia web-based Navigatore HCV-Network; differences in SVR12 across regimens were evaluated by logistic regression. Results: Of the 2082 subjects with HCV-GT3, 1544 were evaluable for comparisons between regimens: SOF + DAC (1023, 66.2%), SOF/VEL (369, 23.9%), GLE/PIB (152, 9.8%). Patients treated with former regimens were more frequently male, cirrhotic, HIV-positive, pretreated, used ribavirin in their regimen, and had lower baseline HCV-RNA. SVR12 was similar across groups: 94.8% in SOF + DAC, 97.6% in SOF/VEL, 96.7% in GLE/PIB (P =.065). At univariate analysis, SVR12 was associated with female gender (97.9% vs 94.8%, P =.007) and lower median pretreatment Log10HCV-RNA (5.87 vs 6.20, P =.001). At multivariate logistic regression analysis, treatment with SOF/VEL was associated with a higher likelihood of SVR12 than SOF + DAC, but only in the absence of ribavirin (98% vs 90.3%). Female gender and lower pretreatment HCV-RNA were independently associated with SVR12. Conclusions: In a large real-life setting of HCV-GT3-infected patients with a high proportion of cirrhosis, the success rate was remarkable. The slight advantage of SOF/VEL on SOF + DAC was significant only without ribavirin. The current prescription shift towards novel regimens (ie SOF/VEL and GLE/PIB) in easier-to-treat patients allows ribavirin-free and shorter schedules without mining SVR12 in this <> genotype. © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

KW - daclatasvir

KW - genotype 3

KW - glecaprevir

KW - Hepatitis C

KW - pibrentasvir

KW - ribavirin

KW - sofosbuvir

KW - sustained virological response

KW - velpatasvir

KW - daclatasvir plus sofosbuvir

KW - glecaprevir plus pibrentasvir

KW - sofosbuvir plus velpatasvir

KW - unclassified drug

KW - virus RNA

KW - adult

KW - antiviral therapy

KW - Article

KW - cohort analysis

KW - comparative effectiveness

KW - female

KW - hepatitis C

KW - Hepatitis C virus genotype 3

KW - human

KW - Human immunodeficiency virus infected patient

KW - liver cirrhosis

KW - longitudinal study

KW - major clinical study

KW - male

KW - multicenter study

KW - sex difference

KW - sustained virologic response

KW - treatment duration

KW - treatment response

U2 - 10.1111/liv.14386

DO - 10.1111/liv.14386

M3 - Article

VL - 40

SP - 769

EP - 777

JO - Liver Int.

JF - Liver Int.

SN - 1478-3223

IS - 4

ER -

Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort: Liver International

Abstract

Keywords

Access to Document

Fingerprint

Cite this